Sunday, July 14, 2019

A new treatment for refractory multiple myeloma

Dr KK Aggarwal

Selinexor (Xpovio) tablet in combination with dexamethasone has received FDA approval as treatment option for the adult patients with multiple myeloma with no available therapy.

Indication: Treatment of adult patients with relapsed refractory multiple myeloma who have received at least four prior therapies and whose disease is resistant to several other forms of treatment, including at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody

Side effects: Leukopenia, neutropenia, thrombocytopenia, anemia, vomiting, nausea, fatigue, diarrhea, fever, decreased appetite and weight, constipation, upper respiratory tract infections and hyponatremia.


·         Monitor patients for low blood counts, platelets and sodium levels.
·         Avoid taking this drug along with other medications that may cause dizziness or confusion and avoid situations where dizziness may be a problem.
·         Health care professionals should optimize the patient’s hydration status, blood counts and other medications to avoid dizziness or confusion.

(Source: FDA)

Dr KK Aggarwal
Padma Shri Awardee
President Elect Confederation of Medical Associations in Asia and Oceania   (CMAAO)
Group Editor-in-Chief IJCP Publications
President Heart Care Foundation of India
Past National President IMA

No comments:

Post a Comment